Buscar
Congreso SOLACI
HomeInternational CongressesACC 2024

ACC 2024

Ver Categoría
Structural Heart Disease

ACC 2024 | ORBITA-COSMIC

Coronary sinus reduction (CSR) is a relevant area of study for the treatment of refractory angina, with...
solaci -
Ver más
Femoropopliteal

ACC 2024 | IVUS-DCB

Drug-coated balloons (DCB) have proven to be effective in the treatment of femoropopliteal pathology, although they entail...
solaci -
Ver más
Acute coronary syndromes

ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive...
solaci -
Ver más
Structural heart disease

ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus

Patients with severe aortic stenosis and a small aortic annulus face an increased risk of deteriorated valvular...
solaci -
Ver más
Structural heart disease

ACC 2024 | DEDICATE Trial: Transcatheter or Surgical Treatment of Aortic Valve Stenosis

In recent years, TAVR has been increasingly used; however, when it comes to younger, lower risk patients,...
solaci -
Ver más
Chronic Ischemic cardiopathy

ACC 2024 | PREVENT Study

The use of intravascular imaging to identify vulnerable plaque (VP) has proven to be very useful, as...
solaci -
Ver más
Acute coronary syndromes

ACC 2024 | DanGer-Shock Trial

Cardiogenic shock will develop in approximately 10% of patients with ST elevated acute MI (STEMI), and unfortunately,...
solaci -
Ver más
Antiplatelet

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TCT 2024 | FAVOR III EUROPA

Dr. Carlos Fava - 0
The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

Dr. Carlos Fava - 0
This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Dr. Omar Tupayachi - 0
Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

Noticias Institucionales

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Arequipa Sessions 2024: Meet the International Guests

solaci - 0
The Arequipa Sessions 2024 is getting closer and closer. Meet the international guests who will share their knowledge for 2 days at a high-level...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad